Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Catalyst Pharmaceuticals (CPRX) has announced it will release its fourth quarter and full-year 2024 financial results after market close on February 26, 2025. The company will host a conference call and webcast the following day, February 27, 2025, at 8:30 AM ET, where management will discuss financial results and provide a business update.
The conference call will be accessible via US/Canada dial-in number (877) 407-8912 and international dial-in (201) 689-8059. A webcast will be available under the Investors section on the company's website, with a replay accessible for at least 30 days following the event.
Catalyst Pharmaceuticals (CPRX) ha annunciato che pubblicherà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 dopo la chiusura del mercato il 26 febbraio 2025. L'azienda ospiterà una conferenza telefonica e trasmetterà in diretta il giorno successivo, 27 febbraio 2025, alle 8:30 AM ET, durante la quale la direzione discuterà i risultati finanziari e fornirà un aggiornamento aziendale.
La conferenza telefonica sarà accessibile tramite il numero di accesso per Stati Uniti/Canada (877) 407-8912 e il numero di accesso internazionale (201) 689-8059. Una trasmissione in diretta sarà disponibile nella sezione Investitori sul sito web dell'azienda, con una registrazione accessibile per almeno 30 giorni dopo l'evento.
Catalyst Pharmaceuticals (CPRX) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el 26 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica y transmitirá en vivo al día siguiente, 27 de febrero de 2025, a las 8:30 AM ET, donde la dirección discutirá los resultados financieros y proporcionará una actualización del negocio.
La conferencia telefónica será accesible a través del número de acceso para EE. UU./Canadá (877) 407-8912 y el número de acceso internacional (201) 689-8059. Una transmisión en vivo estará disponible en la sección de Inversores en el sitio web de la empresa, con una repetición accesible durante al menos 30 días después del evento.
Catalyst Pharmaceuticals (CPRX)는 2024년 4분기 및 연간 재무 결과를 2025년 2월 26일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 다음 날인 2025년 2월 27일 오전 8시 30분 ET에 경영진이 재무 결과를 논의하고 비즈니스 업데이트를 제공하는 전화 회의를 개최할 것입니다.
전화 회의는 미국/캐나다 다이얼인 번호 (877) 407-8912 및 국제 다이얼인 (201) 689-8059를 통해 접근할 수 있습니다. 회사 웹사이트의 투자자 섹션에서 웹캐스트가 제공되며, 이벤트 후 최소 30일 동안 재생할 수 있습니다.
Catalyst Pharmaceuticals (CPRX) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 après la fermeture du marché le 26 février 2025. L'entreprise organisera une conférence téléphonique et diffusera un webinaire le lendemain, le 27 février 2025, à 8 h 30 ET, où la direction discutera des résultats financiers et fournira une mise à jour de l'entreprise.
La conférence téléphonique sera accessible via le numéro de connexion pour les États-Unis/Canada (877) 407-8912 et le numéro international (201) 689-8059. Un webinaire sera disponible dans la section Investisseurs du site web de l'entreprise, avec une rediffusion accessible pendant au moins 30 jours suivant l'événement.
Catalyst Pharmaceuticals (CPRX) hat angekündigt, dass die Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 nach Marktschluss am 26. Februar 2025 veröffentlicht werden. Das Unternehmen wird am folgenden Tag, dem 27. Februar 2025, um 8:30 Uhr ET eine Telefonkonferenz abhalten und einen Webcast anbieten, in dem das Management die Finanzergebnisse besprechen und ein Unternehmensupdate geben wird.
Die Telefonkonferenz ist über die US/Canada Durchwahl (877) 407-8912 und die internationale Durchwahl (201) 689-8059 erreichbar. Ein Webcast wird im Bereich Investoren auf der Website des Unternehmens verfügbar sein, mit einer Wiederholung, die mindestens 30 Tage nach der Veranstaltung zugänglich ist.
- None.
- None.
The Company will Host a Conference Call and Webcast on February 27, 2025, at 8:30 AM ET
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.
Catalyst's management team will host a conference call and webcast on Thursday, February 27, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update.
| Conference Call & Webcast Details | ||
| Date: | February 27, 2025 | |
| Time: | 8:30 AM ET | |
| US/Canada Dial-in Number: | (877) 407-8912 | |
| International Dial-in Number: | (201) 689-8059 | |
The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for at least 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, FL, was recognized on the Forbes 2025 list as one of America's most successful mid-cap companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s fastest-growing companies.
For more information, please visit Catalyst's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals (CPRX) release Q4 and full-year 2024 earnings?
What time is the CPRX Q4 2024 earnings conference call?
How can investors access the CPRX Q4 2024 earnings call?
How long will the CPRX Q4 2024 earnings webcast replay be available?
